Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial,JAMA Oncology

当前位置： X-MOL 学术 › JAMA Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial
JAMA Oncology ( IF 28.4 ) Pub Date : 2024-04-25 , DOI: 10.1001/jamaoncol.2024.0584
Vanita Noronha _{1,

2} , Vijay Patil _{1,

2} , Nandini Menon _{1,

2} , Minit Shah _{1,

2} , Anuradha Chougule _{1,

2} , Zoya Peelay _{1,

2} , Kumar Prabhash _{1,

2}

Affiliation

This randomized clinical trial examines whether adding chemotherapy with pemetrexed and carboplatin to gefitinib improves survival among patients with epidermal growth factor receptor (EGFR)–variant non–small cell lung cancer.

中文翻译：